Breaking News Instant updates and real-time market news.

MOR

MorphoSys

$37.10 /

-0.44 (-1.17%)

, INCY

Incyte

$76.44 /

-1.44 (-1.85%)

09:36
01/13/20
01/13
09:36
01/13/20
09:36

MorphoSys, Incyte announce collaboration and license agreement for tafasitamab

MorphoSys (MOR) and Incyte (INCY) announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary anti-CD19 antibody tafasitamab globally. Tafasitamab is an Fc-engineered antibody against CD19 currently in clinical development for the treatment of B cell malignancies. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S. "The global partnership with Incyte is an important step towards unlocking the full potential of tafasitamab and achieving our goal of rapidly bringing tafasitamab to patients inside and outside of the U.S.," said Jean-Paul Kress, CEO of MorphoSys. "The combination of our strong antibody and drug development expertise partnered with Incyte's well-established hematology-oncology experience and their commercial operations in key territories has the potential to significantly broaden the tafasitamab opportunity. Under the terms of the agreement, MorphoSys will receive an upfront payment of $750M and, in addition, Incyte will make an equity investment into MorphoSys of $150M in new American Depositary Shares of MorphoSys at a premium to the share price at signing of the agreement. Depending on the achievement of certain developmental, regulatory and commercial milestones, MorphoSys will be eligible to receive milestone payments amounting to up to $1.1B. MorphoSys will also receive tiered royalties on ex-U.S. net sales of tafasitamab in a mid-teens to mid-twenties percentage range of net sales.less than/pgreater thanless thanpgreater thanIn the U.S., MorphoSys and Incyte will co-commercialize tafasitamab, with MorphoSys leading the commercialization strategy and booking all revenues from sales of tafasitamab. Incyte and MorphoSys will be jointly responsible for commercialization activities in the U.S. and will share profits and losses on a 50:50 basis. Outside the U.S., Incyte will have exclusive commercialization rights, and will lead the commercialization strategy and book all revenues from sales of tafasitamab, paying MorphoSys royalties on ex-U.S. net sales. Furthermore, the companies will share development costs associated with global and U.S.-specific trials at a rate of 55% (Incyte) to 45% (MorphoSys); Incyte will cover 100% of the future development costs for trials that are specific to ex-U.S. countries. Both parties have agreed to co-develop tafasitamab broadly in relapsed/refractory diffuse large B cell lymphoma, frontline DLBCL as well as additional indications beyond DLBCL, such as follicular lymphoma, marginal zone lymphoma and chronic lymphocytic leukemia. Incyte will be responsible for initiating a combination study of its investigational PI3K-delta inhibitor parsaclisib and tafasitamab in r/r B cell malignancies. Further, Incyte will be responsible for leading any potential registration-enabling studies in CLL and a phase 3 trial in r/r FL/MZL. MorphoSys will continue to be responsible for its currently ongoing clinical trials of tafasitamab in non-Hodgkin lymphoma, CLL, r/r DLBCL and frontline DLBCL. The parties will share responsibility in starting additional global trials, and Incyte intends to pursue development in additional territories including Japan and China. MorphoSys recently submitted a Biologics License Application for tafasitamab, in combination with lenalidomide, to the U.S. Food and Drug Administration for the treatment of r/r DLBCL; the FDA decision regarding a potential approval is expected by mid-2020. The submission of a Marketing Authorization Application to the European Medicines Agency (EMA) in r/r DLBCL is planned for mid-2020. The agreement between MorphoSys and Incyte, including the equity investment, is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act as well as by the German and Austrian antitrust authorities, and will become effective as soon as these conditions have been met.

MOR

MorphoSys

$37.10 /

-0.44 (-1.17%)

INCY

Incyte

$76.44 /

-1.44 (-1.85%)

  • 13

    Jan

  • 13

    Feb

  • 19

    Mar

  • 30

    May

MOR MorphoSys
$37.10 /

-0.44 (-1.17%)

11/19/19 DBAB
MorphoSys news a best case scenario, says Deutsche Bank
11/19/19 GUGG
MorphoSys initiated with a Buy at Guggenheim
11/20/19 GUGG
Guggenheim starts MorphoSys with Buy rating, EUR 126 price target
12/10/19 PIPR
MorphoSys sounds close to locking in MOR208 partner, says Piper Jaffray
INCY Incyte
$76.44 /

-1.44 (-1.85%)

01/03/20 RBCM
Incyte price target lowered to $80 from $85 at RBC Capital
01/03/20
Fly Intel: Top five analyst downgrades
01/03/20 STFL
Stifel says Incyte setback means Equillium may have most advanced aGVHD product
01/09/20 BMOC
Constellation downgraded to Market Perform from Outperform at BMO Capital

TODAY'S FREE FLY STORIES

Syndicate
Xenon Pharmaceuticals 3.75M share Spot Secondary priced at $16.00 » 20:52
01/22/20
01/22
20:52
01/22/20
20:52
XENE

Xenon Pharmaceuticals

$16.84 /

+0.15 (+0.90%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22
    Jan
Syndicate
ImmunoGen 21.325M share Spot Secondary priced at $4.25 » 20:51
01/22/20
01/22
20:51
01/22/20
20:51
IMGN

ImmunoGen

$4.67 /

-0.04 (-0.85%)

The deal size was…

The deal size was increased to $90.6M from $75M. Jefferies, Cowen and William Blair are acting as joint book running managers for the offering.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21
    Jan
Syndicate
SI-Bone 4.3M share Secondary priced at $21.50 per share » 20:34
01/22/20
01/22
20:34
01/22/20
20:34
SIBN

SI-Bone

$22.03 /

+0.13 (+0.59%)

Morgan Stanley and BofA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23
    Jan
Earnings
Notable companies reporting before tomorrow's open » 20:25
01/22/20
01/22
20:25
01/22/20
20:25
PG

Procter & Gamble

$126.31 /

+0.2 (+0.16%)

, UNP

Union Pacific

$181.16 /

-1.34 (-0.73%)

, KMB

Kimberly-Clark

$144.55 /

-0.04 (-0.03%)

, VFC

VF Corp.

$94.55 /

-0.08 (-0.08%)

, LUV

Southwest

$53.48 /

-0.06 (-0.11%)

, MTB

M&T Bank

$161.91 /

+1.025 (+0.64%)

, KEY

KeyCorp

$19.62 /

+0.115 (+0.59%)

, HBAN

Huntington Bancshares

$14.75 /

+0.135 (+0.92%)

, AAL

American Airlines

$27.32 /

+0.11 (+0.40%)

, JBLU

JetBlue

$19.80 /

+0.71 (+3.72%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Procter & Gamble (PG), consensus $1.37... Union Pacific (UNP), consensus $2.04... Kimberly-Clark (KMB), consensus $1.70... V.F. Corp. (VFC), consensus $1.21... Southwest Airlines (LUV), consensus $1.09... M&T Bank (MTB), consensus $3.47... KeyCorp (KEY), consensus 48c... Huntington Bancshares (HBAN), consensus 31c... American Airlines (AAL), consensus $1.15... JetBlue Airways (JBLU), consensus 55c.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Aspen Aerogels initiated with a Buy at B. Riley FBR » 20:19
01/22/20
01/22
20:19
01/22/20
20:19
ASPN

Aspen Aerogels

$10.33 /

+0.36 (+3.61%)

B. Riley FBR initiated…

B. Riley FBR initiated coverage of Aspen Aerogels with a Buy rating and $13 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Synthorx trading halted, pending information request  19:53
01/22/20
01/22
19:53
01/22/20
19:53
THOR

Synthorx

$67.99 /

+ (+0.00%)

 
ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
PG&E reaches agreement with ad hoc noteholder committee » 19:36
01/22/20
01/22
19:36
01/22/20
19:36
PCG

PG&E

$12.55 /

-0.66 (-5.00%)

PG&E Corporation and…

PG&E Corporation and Pacific Gas and Electric Company have reached an agreement with all claim holders who executed commitment letters in support of the alternative Chapter 11 Plan of Reorganization filed by the Ad Hoc Committee of Senior Unsecured Noteholders in PG&E's Chapter 11 cases. The Ad Hoc Noteholder Committee will withdraw its Alternative Plan of Reorganization and support the PG&E Plan upon entry of an order approving the Restructuring Support Agreement by the Bankruptcy Court. The agreement resolves all issues related to the treatment of pre-petition funded debt of the utility, including post-petition interest amounts and make-whole premiums, under PG&E's Chapter 11 Plan of Reorganization.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Coastal Community Bank names Andrew Stines chief risk officer » 19:11
01/22/20
01/22
19:11
01/22/20
19:11
CCB

Coastal Financial

$17.29 /

-0.18 (-1.03%)

Coastal Community Bank…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Fly Intel: After Hours Movers » 19:00
01/22/20
01/22
19:00
01/22/20
19:00
SLM

Sallie Mae

$9.09 /

+0.25 (+2.83%)

, TER

Teradyne

$73.57 /

+2.04 (+2.85%)

, PTC

PTC

$80.06 /

+1.13 (+1.43%)

, STLD

Steel Dynamics

$32.02 /

+0.11 (+0.34%)

, CTXS

Citrix

$119.16 /

+1.37 (+1.16%)

, PAYC

Paycom

$303.73 /

+3.96 (+1.32%)

, FUL

H.B. Fuller

$49.18 /

+0.095 (+0.19%)

, TXN

Texas Instruments

$133.38 /

+2.53 (+1.93%)

, IMGN

ImmunoGen

$4.67 /

-0.04 (-0.85%)

, XENE

Xenon Pharmaceuticals

$16.84 /

+0.15 (+0.90%)

, AVNW

Aviat Networks

$14.70 /

+0.09 (+0.62%)

UP AFTER EARNINGS: Sallie…

UP AFTER EARNINGS: Sallie Mae (SLM) up 21.0%... Teradyne (TER) up 9.4%... PTC Inc (PTC) up 8.0%... Steel Dynamics (STLD) up 5.6%... Citrix (CTXS) up 4.7%. ALSO HIGHER: Paycom (PAYC) up 4.2% after entering S&P500 index. DOWN AFTER EARNINGS: HB Fuller (FUL) down 1.6%... Texas Instruments (TXN) down 1.3%. ALSO LOWER: Immunogen (IMGN) down 3.4% after equity offering... Xenon Pharma (XENE) down 2.9% after equity offering... Aviat Networks (AVNW) down 2.1% after cutting Q2, FY20 guidance due to cyberattack. Movers as of 18:40ET.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22
    Jan
  • 21
    Jan
Syndicate
Tetraphase announces $17.5M of financings priced at-the-market » 18:50
01/22/20
01/22
18:50
01/22/20
18:50
TTPH

Tetraphase

$3.84 /

+0.97 (+33.80%)

Tetraphase…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
J.M. Smucker initiated with a Hold at Jefferies » 18:39
01/22/20
01/22
18:39
01/22/20
18:39
SJM

J.M. Smucker

$107.00 /

-0.77 (-0.71%)

Jefferies analyst Rob…

Jefferies analyst Rob Dickerson initiated coverage of J.M. Smucker with a Hold rating and $109 price target. The analyst notes that at 11-times his expected EBITDA, the stock is not expensive. However, he is concerned with the company's execution missteps in the pet food business, continued pressure in consumer retail, and volatility in its coffee business, which have led to flat revenues and profits over the past 5 years.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Myriad Genetics submits sPMA application to FDA for myChoice CDx test » 18:37
01/22/20
01/22
18:37
01/22/20
18:37
MYGN

Myriad Genetics

$28.71 /

+0.34 (+1.20%)

Myriad Genetics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Hershey initiated with a Hold at Jefferies » 18:36
01/22/20
01/22
18:36
01/22/20
18:36
HSY

Hershey

$152.45 /

-0.355 (-0.23%)

Jefferies analyst Rob…

Jefferies analyst Rob Dickerson initiated coverage of Hershey with a Hold rating and $157 price target. The analyst is positive on the company's "solid top brands, pricing power, and under-levered balance sheet", but he also cites its sub-2% organic growth since Q4 of 2016, limited margin expansion potential, and a 35% valuation premium relative to the sector average, which he believes "appropriately discount" Hersey's expected free cash flow growth and optionality.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Piper Sandler says 'incrementally positive' on Deciphera » 18:32
01/22/20
01/22
18:32
01/22/20
18:32
DCPH

Deciphera

$66.79 /

+0.2 (+0.30%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
B&G Foods initiated with a Hold at Jefferies » 18:28
01/22/20
01/22
18:28
01/22/20
18:28
BGS

B&G Foods

$16.25 /

+0.195 (+1.21%)

Jefferies analyst Rob…

Jefferies analyst Rob Dickerson initiated coverage of B&G Foods with a Hold rating and $15 price target. The analyst cites the company's decelerating tracked-channel retail trends, relatively low gross margin, 500bps decline in operating margin over the past 5 years, high leverage with an industry-high dividend yield, and little available cash to invest in brand support.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Calavo Growers initiated with a Hold at Jefferies » 18:25
01/22/20
01/22
18:25
01/22/20
18:25
CVGW

Calavo Growers

$80.49 /

+0.23 (+0.29%)

Jefferies analyst Rob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Lamb Weston assumed with a Hold at Jefferies » 18:21
01/22/20
01/22
18:21
01/22/20
18:21
LW

Lamb Weston

$91.19 /

+0.01 (+0.01%)

Jefferies analyst Rob…

Jefferies analyst Rob Dickerson assumed coverage of Lamb Weston with a Hold rating and $96 price target. The analyst says the company has benefited from its "impressive" pricing power, limited competition, and large scale over the past 3 years, but as it laps one-off benefits next year, he prefers to be on the sidelines given the near-term deceleration risk for the stock.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Flowers Foods initiated with a Hold at Jefferies » 18:18
01/22/20
01/22
18:18
01/22/20
18:18
FLO

Flowers Foods

$21.75 /

-0.27 (-1.23%)

Jefferies analyst Rob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Kellogg initiated with a Hold at Jefferies » 18:15
01/22/20
01/22
18:15
01/22/20
18:15
K

Kellogg

$70.25 /

-0.32 (-0.45%)

Jefferies analyst Rob…

Jefferies analyst Rob Dickerson initiated coverage of Kellogg with a Hold rating and $74 price target. The analyst notes that if North America cereal consumption trends improve and its emerging market share gains continue, the stock could be an "emerging growth story". Dickerson notes however that the valuation on Kellogg is "fair" as he prefers to see sustainable consumption trend improvements before turning more constructive on the stock.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
General Mills initiated with a Hold at Jefferies » 18:12
01/22/20
01/22
18:12
01/22/20
18:12
GIS

General Mills

$53.97 /

-0.37 (-0.68%)

, WMT

Walmart

$116.10 /

+0.53 (+0.46%)

, K

Kellogg

$70.25 /

-0.32 (-0.45%)

Jefferies analyst Rob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
J & J Snack Foods initiated with a Hold at Jefferies » 18:07
01/22/20
01/22
18:07
01/22/20
18:07
JJSF

J & J Snack Foods

$183.94 /

-0.28 (-0.15%)

Jefferies analyst Rob…

Jefferies analyst Rob Dickerson initiated coverage of J & J Snack Foods with a Hold rating and $200 price target. The analyst is positive on the company's overcapitalized position, clean balance sheet and "sticky" customer base, but he is concerned with its 40-times enterprise value to expected EBITDA valuation, which is nearly an all-time high.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
TreeHouse assumed with a Hold at Jefferies » 18:04
01/22/20
01/22
18:04
01/22/20
18:04
THS

TreeHouse

$46.83 /

-0.085 (-0.18%)

Jefferies analyst Rob…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Hudbay Minerals upgraded to Outperformer from Neutral at CIBC » 18:03
01/22/20
01/22
18:03
01/22/20
18:03
HBM

Hudbay Minerals

$3.41 /

-0.12 (-3.40%)

CIBC analyst Oscar…

CIBC analyst Oscar Cabrera upgraded Hudbay Minerals to Outperformer from Neutral with a price target of $8, up from $5. The analyst, after rolling over his estimates to 2021, cites the company's flat or increasing copper equivalent production and improving free cash flow generation for the upgrade.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Turquoise Hill upgraded to Outperformer from Neutral at CIBC » 18:02
01/22/20
01/22
18:02
01/22/20
18:02
TRQ

Turquoise Hill

$0.68 /

-0.0221 (-3.15%)

CIBC analyst Oscar…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
Steel Dynamics CEO says company 'constructive' regarding NA steel market » 18:02
01/22/20
01/22
18:02
01/22/20
18:02
STLD

Steel Dynamics

$32.02 /

+0.11 (+0.34%)

"Based on domestic…

"Based on domestic steel demand fundamentals, we are constructive regarding North American steel market dynamics," said Millett. "We believe North American steel consumption will experience modest growth and will be supported by further steel import reductions and the end of steel inventory destocking. We believe recent and possible trade actions could have a positive impact in further reducing unfairly traded steel imports into the United States, including coated flat roll steel, which could have a significant positive impact for Steel Dynamics, as we are the largest non-automotive flat roll steel coater in the United States. In combination with our existing and newly announced expansion initiatives, there are firm drivers in place for our continued growth. We are excited about our Sinton, Texas flat roll steel mill project, and the associated long-term value creation it will bring through geographic and value-added product diversification. This facility is designed to have product size and quality capabilities beyond that of existing electric-arc-furnace flat roll steel producers, competing even more effectively with the integrated steel model and foreign competition. We have targeted regional markets that represent over 27 million tons of relevant flat roll steel consumption, which includes the growing Mexican flat roll steel market. This facility is located and designed to have a meaningful competitive advantage in those regions. The team began site work in the second half of 2019, and we are excited to announce that we recently received the required environmental permitting to allow for full construction efforts to begin, with current plans to commence operations mid-year 2021. Our differentiated business model and performance-driven culture clearly demonstrate our through-cycle earnings capability. We continue to strengthen our financial position through consistent strong cash flow generation and the execution of our long-term strategy. We are competitively positioned and remain focused on delivering long-term value creation for all of our stakeholders," concluded Millett.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.